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Systematic Review ajog.orgFetal fibronectin testing for prevention of preterm
birth in singleton pregnancies with threatened
preterm labor: a systematic review and
metaanalysis of randomized controlled trials
Vincenzo Berghella, MD; Gabriele Saccone, MDOBJECTIVE DATA: Fetal fibronectin is an extracellular matrix glycoprotein that is produced by amniocytes and cytotrophoblasts and has
been shown to predict spontaneous preterm birth.
STUDY: The aim of this systematic review and metaanalysis of randomized clinical trials was to evaluate the effect of the use of fetal
fibronectin in the prevention of preterm birth in singleton pregnancies with threatened preterm labor.
STUDY APPRAISAL AND SYNTHESIS METHODS: The research was conducted with the use of MEDLINE, EMBASE, Web of Sciences,
Scopus, ClinicalTrial.gov, OVID, and Cochrane Library as electronic databases from the inception of each database to February 2016.
Selection criteria included randomized clinical trials of singleton gestations with threatened preterm labor that were assigned randomly
to management based on fetal fibronectin results (ie, intervention group) or not (ie, comparison group). Types of participants included
women with singleton gestations at 23 0/7 to 34 6/7 weeks with threatened preterm labor. Studies that included management that was
also based on the use of sonographic cervical length were excluded. The primary outcome was preterm birth at <37 weeks of
gestation. The summary measures were reported as relative risk or as mean differences with 95% confidence interval.
RESULTS: Six trials that included 546 singleton gestations with symptoms of preterm labor were included in the metaanalysis. The
overall risk of bias of the included trials was low. Women were eligible for the random assignment in case of symptoms that suggested
preterm labor at 23e34 weeks of gestation. During admission, before digital examination, a Dacron swab was rotated in the posterior
fornix for 10 seconds to absorb cervicovaginal secretions that were then analyzed for the fetal fibronectin qualitative method, with
results reported as either positive or negative. Women who were assigned randomly to the fetal fibronectin group had a similar
incidence of preterm birth at <37 weeks of gestation (20.7% vs 29.2%; relative risk, 0.72; 95% confidence interval, 0.52e1.01), at
<34 weeks of gestation (8.3% vs 7.9%; relative risk, 1.09; 95% confidence interval, 0.54e2.18), at<32 weeks of gestation (3.3% vs
5.6%; relative risk, 0.64; 95% confidence interval, 0.24e1.74), and at <28 weeks of gestation (1.1% vs 1.7%; relative risk, 0.74;
95% confidence interval, 0.15e3.67) compared with the control group. No differences were found in the number of women who
delivered within 7 days (12.8% vs 14.5%; relative risk, 0.76; 95% confidence interval, 0.47e1.21), in the mean of gestational age at
delivery (mean difference, 0.20 week; 95% confidence interval, e0.26 to 0.67), in the rate of maternal hospitalization (27.4% vs
26.9%; relative risk, 1.07; 95% confidence interval, 0.80e1.44), in the use of tocolysis (25.3% vs 28.2%; relative risk, 0.97; 95%
confidence interval, 0.75e1.24), antenatal steroids (29.2% vs 29.2%; relative risk, 1.05; 95% confidence interval, 0.79e1.39), in the
mean time in the triage unit (mean difference, 0.60 hour; 95% confidence interval, e0.03 to 1.23) and in neonatal outcomes that
included respiratory distress syndrome (1.3% vs 1.5%; relative risk, 0.91; 95% confidence interval, 0.06e14.06), and admission to
the neonatal intensive care unit (19.4% vs 8.1%; relative risk, 2.48; 95% confidence interval, 0.96e6.46). Management based on the
fetal fibronectin test required higher hospitalization charges (mean difference, $153; 95% confidence interval, 24.01e281.99).
CONCLUSION: Fetal fibronectin testing in singleton gestations with threatened preterm labor is not associated with the prevention of
preterm birth or improvement in perinatal outcome but is associated with higher costs.
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FIGURE 1
Flow diagram of studies
identified in the systematic
review
Flow diagram using PRISMA template (preferred
reporting item for systematic reviews and
metaanalyses).
RCTs, randomized controlled trials.
Berghella. Fibronectin and preterm labor. Am J Obstet
Gynecol 2016.
Systematic Review ajog.orgpontaneous preterm birth (SPTB)S remains the number 1 cause of
perinatal morbidity and death in many
countries, including the United States.1
Deaths and morbidities, which include
respiratory distress syndrome, intra-
ventricular hemorrhage, necrotizing
enterocolitis, and sepsis, are associated432 American Journal of Obstetrics& Gynecologyinversely with gestational age at birth.1
All members of a family in which an
SPTB occurs are affected greatly in
several aspects including medical, social,
psychological, and ﬁnancial.2
Fetal ﬁbronectin (FFN) is an extracel-
lular matrix glycoprotein that is
produced by amniocytes and cyto-
trophoblasts and is seen throughout
gestation in all pregnancies. FFN can be
detected in cervical and vaginal secretions
at <20 weeks of gestation, and very low
levels are found at>22weeks of gestation
(<50 ng/mL). Levels 50 ng/mL at >22
weeks of gestation has been associated
with an increased risk of SPTB.3 The
efﬁcacy of FFN in the prediction of SPTB
has been assessed in several populations
that include asymptomatic women and
women with preterm labor (PTL).4
The aim of this systematic review and
metaanalysis of randomized clinical
trials (RCTs) was to evaluate the effec-
tiveness of the management of singleton
pregnancies with threatened PTLwith or
without knowledge of FFN testing for
the prevention of PTB.
Methods
Search strategy
This metaanalysis was performed ac-
cording to a protocol recommended for
systematic review.5 The review protocol
was designed a priori to deﬁne methods
for collecting, extracting, and analyzing
data. The research was conducted with
the use of MEDLINE, EMBASE, Web of
Sciences, Scopus, ClinicalTrial.gov,
OVID, and Cochrane Library as elec-
tronic databases. The trials were identi-
ﬁed with the use of a combination of the
following text words: “fetal ﬁbronectin,”
“preterm labor,” “threatened,” “predic-
tion,” “prevention,” “birth,” “delivery,”
“prematurity,” “neonatal,” and “ran-
domized” from the inception of each
database to February 2016. Review of
articles also included the abstracts of all
references that were retrieved from the
search.
Study selection
Selection criteria included RCTs of
singleton gestations with threatened PTL
that were assigned randomly to man-
agement based on FFN results (ie,OCTOBER 2016intervention group) or not (ie, compar-
ison group). We included both studies in
which FFN was collected on all women
and studies in which FFN screening was
done only on women who were assigned
randomly to the FFN group. In the
studies in which FFN was collected on all
women, womenwere assigned randomly
so that, in 50% of them, the result was
available to them and the managing
obstetrician, and, in 50% of them, the
FFN was blinded to them and the
managing obstetricians. Types of par-
ticipants included womenwith singleton
gestations at 23 0/7 to 34 6/7 weeks of
gestation with threatened PTL.
Studies that included management
that was based also on the use of sono-
graphic cervical length were excluded.
Quasirandomized trials (ie, trials in
which allocationwas done on the basis of
a pseudo-random sequence [eg, odd/
even hospital number or date of birth]
alternation) and studies on multiple
pregnancies were also excluded.
Data extraction and risk of bias
assessment
The risk of bias in each included study
was assessed by the use of the criteria
outlined in the Cochrane Handbook for
Systematic Reviews of Interventions.5
Seven domains that are related to risk
of bias were assessed in each included
trial because there is evidence that
these issues are associated with biased
estimates of treatment effect: (1) random
sequence generation, (2) allocation
concealment, (3) blinding of participants
and personnel, (4) blinding of outcome
assessment, (5) incomplete outcome
data, (6) selective reporting, and (7)
other bias. Review authors’ judgments
were categorized as “low risk,” “high
risk,” or “unclear risk” of bias.5
All analyses were done with an
intention-to-treat approach; conditions
were evaluated according to the treatment
group to which they were allocated
randomly in the original trials. The pri-
mary outcome was the incidence of PTB
<37weeks. Secondary maternal outcomes
were PTB at<34,<32, and<28 weeks of
gestation, delivery within 7 days, mean
gestational age at delivery (in weeks),
maternal hospitalization, tocolysis, use of
FIGURE 2
Assessment of risk of bias
A, Summary of risk of bias for each trial. A plus sign indicates a low risk of bias; a minus sign indicates a high risk of bias; a question mark indicates an
unclear risk of bias. B, Risk of bias graph about each risk of bias item presented as percentages across all included studies.
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ajog.org Systematic Reviewantenatal steroids, mean time to evaluate
(in hours), neonatal outcomes (ie, inci-
dence of respiratory distress syndrome and
of admission to neonatal intensive care
unit) and hospitalization charges. Data
from each eligible study were extracted
withoutmodiﬁcation of original data onto
custom-made data collection forms. Data
not present in the original publications
were requested from all the principal
investigators.
Data analysis
The data analysis was completed inde-
pendently by the authors who used
ReviewManager (version 5.3; TheNordic
Cochrane Centre, Cochrane Collabora-
tion, 2014, Copenhagen,Denmark).5 The
completed analyses were then compared,
and any difference was resolved with re-
view of the entire data and independent
analysis. Between-study heterogeneity
was explored with the I2 statistic, which
represents the percentage of between-study variation that is due to heteroge-
neity rather than chance. A value of 0%
indicates no observed heterogeneity,
whereas I2 values of 50% indicate a
substantial level of heterogeneity. A ﬁxed
effects model was used if substantial sta-
tistical heterogeneity was not present. On
the contrary, if there was evidence of
signiﬁcant heterogeneity between the
studies that were included, a random ef-
fect model was used.5
Potential publication biases were
assessed statistically with Begg’s and
Egger’s tests.5 A probability value of<.05
was considered statistically signiﬁcant.
Tests for funnel plot asymmetry were
carried out with only an exploratory aim
when the total number of publications
that were included for each outcome was
<10. In this case, the power of the tests
was too low to distinguish chance from
real asymmetry.
The summary measures were re-
ported as relative risk (RR) or as meanOCTOBER 2016 Amdifference (MD) with 95% conﬁdence
interval (CI).
All review stages were conducted
independently by the authors who
independently assessed electronic
search, eligibility of the studies, inclusion
criteria, risk of bias, data extraction, and
data analysis. Disagreements were
resolved by discussion.
The metaanalysis was reported ac-
cording to the Preferred Reporting Item
for Systematic Reviews and Meta-
analyses (PRISMA) statement.6 Before
data extraction, the review was registered
with the PROSPERO International Pro-
spective Register of Systematic Reviews
(registration No.: CRD42016035939).
Results
Study selection and study
characteristics
Figure 1 shows the ﬂow diagram
(PRISMA template) of information
derived from the review of potentiallyerican Journal of Obstetrics& Gynecology 433
TABLE 1
Characteristics of the included trials
Study location
Nguyen et al, 20027 Plaut et al, 20038 Grobman et al, 20049 Lowe et al, 200410
Dutta and Norman,
201111 Lee et al, 201312
United States United States and Canada United States United States United Kingdom United States
Sample sizea 77 (42 vs 35) 108 (51 vs 57) 100 (50 vs 50) 97 (46 vs 51) 88 (44 vs 44) 76 (44 vs 32)
Inclusion criteria Singleton gestations
with symptoms of
preterm labor
Singleton gestations with
symptoms of preterm labor
Singleton gestations with
symptoms of preterm labor
Singleton gestations
with symptoms of
preterm labor
Singleton gestations
with symptoms of
preterm labor
Singleton
gestations with
symptoms of
preterm labor
Definition of
preterm labor
Uterine contractions,
low back pain, or
bloody showb
Not reported >6 Contractions per hour by
external tocodynometry
Not reported Uterine contractions,
low back pain, pelvic
pressure, or low
abdominal pressure
>3 Contractions per
30 minutes by external
tocodynometry,
abdominal pressure
or cramping, low
back pain
Gestational age
at randomization
(range in weeks)
240e346 240e346 240e346 240e346 240e346 240e336
Exclusion criteria Cervical manipulation or
sexual intercourse within
the previous 24 hours,
ruptured membranes,
gross bleeding, cervical
dilation 3 cm, cerclage
in situ, multiple
pregnancies
Cervical manipulation or sexual
intercourse within the previous
24 hours, ruptured membranes,
gross bleeding, cervical dilation
3 cm, cerclage in situ, multiple
pregnancies
Cervical manipulation or sexual
intercourse within the previous
24 hours, ruptured membranes,
gross bleeding, cervical dilation
3 cm, cerclage in situ,
multiple pregnancies
Cervical manipulation or
sexual intercourse within
the previous 24 hours,
ruptured membranes,
gross bleeding, cervical
dilation 3 cm,
cerclage in situ,
multiple pregnancies
Cervical manipulation
or sexual intercourse
within the previous
24 hours, ruptured
membranes, gross
bleeding, cervical
dilation 3 cm,
cerclage in situ,
multiple pregnancies
Cervical manipulation or
sexual intercourse within
the previous 24 hours,
ruptured membranes,
gross bleeding, cervical
dilation 3 cm, cerclage
in situ, multiple
pregnancies
Fetal fibronectin
immunoassay
test
Adeza Biomedical Adeza Biomedical Adeza Biomedical Adeza Biomedical Not reported Adeza Biomedical
Fetal fibronectin
cut-off
50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL 50 ng/mL
Control group Fetal fibronectin
not done
Fetal fibronectin blinded Fetal fibronectin blinded Fetal fibronectin blinded Fetal fibronectin
blinded
Fetal fibronectin blinded
Previous
spontaneous
preterm birtha
11/42 (26.2%) vs
8/35 (22.9%)b
17/51 (33.3%) vs 25/57
(43.9)
4/50 (8.0%) vs 8/50 (16.0%) 12/46 (26.1%) vs 14/51
(27.5%)
Not reported 12/44 (27.3%) vs
9/32 (28.1%)
Primary outcome Cost-effectiveness Transport to tertiary care centers Health care costs Length of stay Inpatient hospital admission Triage evaluation time
a Data are presented as number in the intervention group (ie, fetal fibronectin group) vs number in the control group; b Additional data provided by the authors of the original trial.
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TABLE 2
Treatment of women according to fetal fibronectin results
Variable
Nguyen et al,
20027
Plaut et al,
20038
Grobman et al,
20049
Lowe et al,
200410
Dutta and Norman,
201111 Lee et al, 201312
Fetal fibronectin
positive
Further
observation
Physician’s
discretiona
Physician’s
discretiona
Physician’s
discretiona
Admit for preterm
labor, administration
of tocolytics and
steroids
Admit for preterm
laborb or discharge
Fetal fibronectin
negative
Discharged
home
Physician’s
discretiona
Physician’s
discretiona
Physician’s
discretiona
Discharged home Discharged home
Fetal fibronectin
blinded or not done
Physician’s
discretion
Physician’s
discretion
Physician’s
discretion
Physician’s
discretion
Physician’s
discretion
Physician’s
discretion
a Decision made by attending physician who was aware of the test results and test characteristics (sensitivity, specificity, and positive and negative predictive value) of the fetal fibronectin assay; b If
cervical change in serial cervical examinations or if persistent contractions.
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ajog.org Systematic Reviewrelevant articles. Eight studies were
assessed for eligibility.7-14 Two studies
were excluded13,14: one study was
excluded because it assessed the efﬁcacyof
FFN in women with previous SPTB13;
Ness et al14 was excluded because the
management was based also on the use of
ultrasound cervical length. Six trials
therefore were included in the meta-
analysis.7-12 Tests for funnel plot asym-
metry were carried out only with an
exploratory aim because the total number
of publications that were included for
each outcome was <10. Despite this, the
overall risk of bias of the included trials
was low (Figure 2). All studies had a low
risk of bias in “random sequence gener-
ation,” “incomplete outcome data,” and
“selective reporting.” Adequate methods
for allocation of women were used. All
randomly assigned womenwere included
in an intention-to-treat analysis. In 3
studies, laboratory personnel who per-
formed the FFN test were blinded to
women’s characteristics and outcomes
(ie, blinding of outcome assessment).8,9,12
Physicians were not blinded to the FFN
assay result. Publication bias, which was
assessed with the use of Begg’s and Egger’s
tests, was not signiﬁcant (P¼ .84 and .91,
respectively). Authors of 4 trials were able
to provide us additional unpublished data
from their studies.7,9,10,12
Table 1 shows the characteristics of the
included trials. Women were eligible for
the randomization in case of symptoms
that suggested PTL between 23 and 34
weeks of gestation. During admission,before digital examination, a Dacron
swab was rotated in the posterior fornix
for 10 seconds to absorb cervicovaginal
secretions that were then analyzed for
the FFN qualitative method, with results
reported as either positive or negative.
Women with cervical manipulation or
sexual intercourse within the previous
24 hours, ruptured membranes, gross
bleeding, cervical dilation 3 cm, cerc-
lage in situ, and multiple pregnancies
were excluded in all the trials. The
treatment of the women was mostly at
the physician’s discretion (Table 2).
Synthesis of results
Table 3 shows the pooled results for the
primary and secondary outcomes. Of the
546 singleton gestations with symptoms
of PTL that were included in the meta-
analysis, 277 gestations (50.7%) were
assigned randomly to the FFN group, and
269 gestations (49.3%) were assigned to
the comparison group. Statistical hetero-
geneity was low with no inconsistency
(I2¼ 0) in the primary outcome.
Compared with control group, women
who were assigned randomly to FFN
group had a similar incidence of PTB at
<37 weeks of gestation (20.7% vs 29.2%;
RR, 0.72; 95% CI, 0.52e1.01; Figure 3),
<34 weeks of gestation (8.3% vs 7.9%;
RR, 1.09; 95%CI, 0.54e2.18),<32weeks
of gestation (3.3% vs 5.6%; RR, 0.64; 95%
CI, 0.24e1.74), and <28 weeks of gesta-
tion (1.1% vs 1.7%; RR, 0.74; 95% CI,
0.15e3.67). No differences were found in
the number of women who deliveredOCTOBER 2016 Amwithin 7 days (12.8% vs 14.5%; RR, 0.76;
95% CI, 0.47e1.21), in the mean of
gestational age at delivery (MD0.20week;
95% CI, e0.26e0.67; Figure 4), in the
rate ofmaternal hospitalization (27.4% vs
26.9%; RR, 1.07; 95% CI, 0.80e1.44), in
use of tocolysis (25.3% vs 28.2%; RR,
0.97; 95% CI, 0.75e1.24; Figure 5),
antenatal steroids (29.2% vs 29.2%; RR,
1.05; 95% CI, 0.79e1.39), in the mean
time in the triage unit (MD, 0.60 hour;
95% CI, e0.03e1.23), and in neonatal
outcomes that included respiratory
distress syndrome (1.3% vs 1.5%; RR,
0.91; 95%CI, 0.06e14.06) and admission
to neonatal intensive care unit (19.4% vs
8.1%; RR, 2.48; 95% CI, 0.96e6.46).
Management based on FFN testing
required higher hospitalization charges
(MD, $153; 95% CI, 24.01e281.99).
Comment
Main ﬁndings
This metaanalysis from 6 low risk of bias
RCTs that included 546 women shows
that FFN testing in singleton gestations
with symptoms of PTL does not reduce
the PTB rate or improve perinatal out-
come, but is associated with higher cost of
approximately $150. Our metaanalysis
represents level-1 data and includes well-
designed RCTs. The test of heterogeneity
and pooled data all point to the non-
efﬁcacy of FFN testing as studied so far.
Comparison with existing literature
Our data support earlier ﬁndings of a
Cochrane review of 5 trials that includederican Journal of Obstetrics& Gynecology 435
TABLE 3
Primary and secondary outcomes
Variable
Nguyen et al,
20027 Plaut et al, 20038
Grobman et al,
20049
Lowe et al,
200410
Dutta and
Norman,
201111 Lee et al, 201312 Total
Relative risk (95%
confidence interval)
Sample sizea 77 (42 vs 35) 108 (51 vs 57) 100 (50 vs 50) 97 (46 vs 51) 88 (44 vs 44) 76 (44 vs 32) 546 (277 vs
269)
—
Preterm birtha
At <37 weeks of
gestation
11/42 (26.2%) vs
9/35 (25.7%)b
5/43 (11.6%) vs
12/47 (25.5%)
10/50 (20.0%) vs
13/50 (26.0%)
13/46 (28.3%) vs
24/51 (47.1%) b
Not reported 7/41 (17.1%) vs
4/29 (13.8%)
46/222 (20.7%) vs
62/212 (29.2%)
0.72 (0.52e1.01)
At <34 weeks of
gestation
Not reported 2/43 (4.7%) vs
2/47 (4.3%)
5/50 (10.0%) vs
3/50 (6.0%)
5/46 (10.9%) vs
9/51 (17.7%) b
Not reported 3/41 (7.3%) vs
0/29
15/180 (8.3%) vs
14/177 (7.9%)
1.09 (0.54e2.18)
At <32 weeks of
gestation
Not reported 2/43 (4.7%) vs
1/47 (2.1%)
3/50 (6.0%) vs
2/50 (4.0%)
1/46 (2.1%) vs
7/51 (13.7%)b
Not reported 0/41 vs 0/29b 6/180 (3.3%) vs
10/177 (5.6%)
0.64 (0.24e1.74)
At <28 weeks of
gestation
Not reported 0/43 vs 0/47 2/50 (4.0%) vs
2/50 (4.0%)
0/46 vs 1/51
(1.9%)b
Not reported 0/41 vs 0/29b 2/180 (1.1%) vs
3/177 (1.7%)
0.74 (0.15e3.67)
Delivery within 7 daysa 1/42 (2.4%) vs
2/35 (5.7%)b
Not reported 2/50 (4.0%) vs
3/50 (6.0%)b
3/46 (6.5%) vs
4/51 (7.8%)b
Not reported 17/41 (41.5%) vs
15/29 (51.7%)b
23/179 (12.8%) vs
24/165 (14.5%)
0.76 (0.47e1.21)
Gestational age at delivery,
wkc
34.22.9 vs
33.72.7b
29.93.2 vs
30.42.7
383 vs 383 38.32.8 vs
37.43.4
38.13.25 vs
38.12.33
38.62.1 vs
38.31.7b
— 0.20 week (e0.26e0.67)
Maternal hospitalizationa 9/42 (21.4%) vs
7/35 (20.0%)b
Not reported 13/50 (26.0%) vs
14/50 (28.0%)
16/46 (34.8%) vs
12/51 (23.5%)
21/44 (47.7%) vs
22/44 (50.0%)
3/44 (6.8%) vs
2/32 (6.3%)
62/226 (27.4%) vs
57/212 (26.9%)
1.07 (0.80e1.44)
Tocolysisa 7/42 (16.7%) vs
7/35 (20.0%)b
25/43 (58.1%) vs
28/47 (59.6%)
8/50 (16.0%) vs
9/50 (18.0%)
22/46 (47.8%) vs
23/51 (45.1%)
3/44 (6.8%) vs
4/44 (9.1%)
3/44 (6.8%) vs
2/32 (6.3%)b
68/269 (25.3%) vs
73/259 (28.2%)
0.97 (0.75e1.24)
Steroidsa 9/42 (21.4%) vs
7/35 (20.0%)b
Not reported 8/50 (16.0%) vs
10/50 (20.0%)
23/46 (50.0%) vs
22/51 (43.1%)
17/44 (38.6%) vs
21/44 (47.7%)
9/44 (20.5%) vs
2/32 (6.3%)b
66/226 (29.2%) vs
62/212 (29.2%)
1.05 (0.79e1.39)
Time in the triage unit, hrc,d 3.31.7 vs
2.71.7
6.38 vs
1028.1
4.123.59 vs
4.493.90b
167.4 vs
124.9
16.825.3 vs
17.725.5
31.8 vs
2.81.6
— 0.60 hour (e0.03e1.23)
Respiratory distress
syndromea
Not reported Not reported Not reported Not reported 1/44 (2.3%) vs
1/40 (2.5%)
0/37 vs 0/27b 1/81 (1.3%) vs
1/67 (1.5%)
0.91 (0.06e14.06)
Admission to neonatal
intensive care unita
Not reported Not reported Not reported Not reported 10/30 (33.3%) vs
3/30 (10.0%)
3/37 (8.1%) vs
2/32 (6.3%)
13/67 (19.4%) vs
5/62 (8.1%)b
2.48 (0.96e6.46)
Hospitalization charges, $c 452381 vs
299175
Not reported Not reported Not reported Not reported Not reported — $153 (24.01e281.99)e
a Data are presented as the number of participants in the fetal fibronectin group vs the number of participants in the control group with percentage; b Additional data obtained from the authors of the original trial; c Data are given as mean standard deviation; d Time
to evaluate; e Statistically significant.
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FIGURE 3
Forest plot for the risk of the primary outcome, PTB <37 weeks
Incidence of preterm birth at<37 weeks of gestation. The rectangles represent the point estimates for each study, the size of the rectangle represents
the weight allocated to each study, and the horizontal lines represent the 95% confidence intervals. The diamond represents the summary estimate and
the size of the diamond represents the 95% confidence intervals.
CI, confidence interval; df, degrees of freedom; FFN, fetal fibronectin; M-H, Mantel-Haenszel.
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ajog.org Systematic Review747 women and concluded that,
although FFN is used commonly in labor
and delivery units to help in the treat-
ment of women with PTL, currently
there is not sufﬁcient evidence to
recommend its use. That Cochrane
reviews also includes asymptomatic
women; our study focused only on
women with threatened PTL.15
Strengths and limitations
Our study has several strengths. This
metaanalysis includes all studies of highFIGURE 4
Forest plot for mean of gestational ag
The rectangles represent the point estimates for ea
lines represent the 95% confidence intervals. Th
confidence intervals.
CI, confidence interval; df, degrees of freedom; FFN, fetal fibronecti
Berghella. Fibronectin and preterm labor. Am J Obstet Gynecolquality and with a low risk of bias ac-
cording to the Cochrane risk of bias tools
that have been published so far on the
topic. To our knowledge, no previous
metaanalysis on this issue is as large, up-
to-date, or comprehensive. We obtained
additional unpublished data for several
outcomes. The protocol of this reviewwas
a priori registered on PROSPERO. Sta-
tistical tests showed no signiﬁcant po-
tential publication biases. Intent-to-treat
analysis was used, and both random and
mixed effects models were used whene at delivery
ch study, the size of the rectangle represents the w
e diamond represents the summary estimate and
n; IV, independent variable.
2016.
OCTOBER 2016 Amappropriate. The statistical heterogeneity
within the studies was very low. We
obtained unpublished data from 47,9,10,12
of the 6 included randomized studies.
These are key elements that are needed to
evaluate the reliability of a metaanalysis.5
Limitations of our study are inherent
to the limitations of the included RCTs.
Only 6 trials were included in the
metaanalysis. The small number of
studies did not permit meaningful
stratiﬁedmetaanalyses to explore the test
performance in subgroups of patienteight allocated to each study, and the horizontal
the size of the diamond represents the 95%
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FIGURE 5
Forest plot for the risk of tocolysis
The rectangles represent the point estimates for each study, the size of the rectangle represents the weight allocated to each study, and the horizontal
lines represent the 95% confidence intervals. The diamond represents the summary estimate and the size of the diamond represents the 95%
confidence intervals.
CI, confidence interval; df, degrees of freedom; FFN, fetal fibronectin; M-H, Mantel-Haenszel.
Berghella. Fibronectin and preterm labor. Am J Obstet Gynecol 2016.
Systematic Review ajog.orgthat may be less or more susceptible to
bias. The small number of included tri-
als, different primary outcome of the
original trials, and different deﬁnition of
PTL represent the major limitations of
this systematic review.
Conclusion and implications
In summary, based on these level-1 data,
there seems (at least as used so far in
these trials) to be no reason to justify the
routine use of FFN in women with
threatened PTL. Given that we found a
nonsigniﬁcant reduction by 28% in the
primary outcome, further study must be
undertaken to better understand
whether and under what circumstances
the predictive characteristics of the FFN
test can be translated into better clinical
management. Currently, the only treat-
ment protocol for screening of women
with threatened PTL that has been
shown by randomized trial data to
decrease PTB has been based mainly on
transvaginal ultrasound cervical length,
with FFN only in women with trans-
vaginal ultrasound cervical length if
20e29 mm.14 -
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